Immix Biopharma Valuation Multiples

Immix Biopharma Overview

About Immix Biopharma

Immix Biopharma Inc is engaged in the discovery and development of novel cell therapies for hematologic malignancies (blood cancers) and other indications. It is a clinical-stage biopharmaceutical company developing a novel class of Tissue-Specific Therapeutics TM in oncology and inflammation. Its TME Normalization Technology allows drug candidates to circulate in the bloodstream, exit through tumor blood vessels and simultaneously attack all components of the TME. Its product candidates include CAR-T NXC-201 for autoimmune diseases, and IMX-110 for treatment of soft tissue sarcoma.

Founded

2012

HQ

Employees

21

Website

immixbio.com

Sectors

BiopharmaceuticalsBioTech

Financials (LTM)

Revenue: —

EBITDA: ($25M)

EV

$412M

Valuation Multiples

Multiples.vc

Start free trial

Immix Biopharma Financials

Immix Biopharma reported last 12-month revenue of — and negative EBITDA of ($25M).

In the same LTM period, Immix Biopharma generated — in gross profit, ($25M) in EBITDA losses, and had net loss of ($28M).

Immix Biopharma P&L

In the most recent fiscal year, Immix Biopharma reported revenue of — and EBITDA of ($23M).

Immix Biopharma expects next 12-month revenue of XXX and NTM EBITDA of XXX

Immix Biopharma Stock Performance

Immix Biopharma has current market cap of $427M, and enterprise value of $412M.

Immix Biopharma's stock price is $8.06.

Immix Biopharma Valuation Multiples

Immix Biopharma trades at (16.2x) EV/EBITDA.

Immix Biopharma Financial Valuation Multiples

As of March 18, 2026, Immix Biopharma has market cap of $427M and EV of $412M.

Equity research analysts estimate Immix Biopharma's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX

Immix Biopharma has a P/E ratio of (15.4x).

Immix Biopharma Margins & Growth Rates

Immix Biopharma's revenue in the last fiscal year grew by —.

Immix Biopharma's revenue per employee in the last FY averaged $0.0M.

Immix Biopharma Public Comps

See public comps and valuation multiples for other Biopharmaceuticals comps.

Immix Biopharma M&A Activity

Immix Biopharma acquired XXX companies to date.

Last acquisition by Immix Biopharma was on XXXXXXXX, XXXXX. Immix Biopharma acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).

Immix Biopharma Investment Activity

Immix Biopharma invested in XXX companies to date.

Immix Biopharma made its latest investment on XXXXXXXX, XXXXX. Immix Biopharma invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).